Parkinson's disease

  title={Parkinson's disease},
  author={Lorraine V. Kalia and Anthony E. Lang},
  journal={The Lancet},
  • L. Kalia, A. Lang
  • Published 4 September 2015
  • Psychology, Medicine, Biology
  • The Lancet

Figures and Tables from this paper

Parkinson's disease
It is shown how personalised management of Parkinson's disease can be optimised and requires a multidisciplinary team approach, including a growing repertoire of non-pharmacological interventions.
2 Aetiology and Pathogenesis of Parkinson ’ s Disease
The term parkinsonism used to describe the motor features of PD – needs to be distinguished from Parkinson’s disease, which implies a clinically and pathologically defined process, often established via the United Kingdom Parkinson's Disease Society (UKPDS) brain bank criteria.
Parkinson's disease and parkinsonism: Clinicopathological discrepancies on diagnosis in three patients
The clinicopathological features of three patients diagnosed as having PSP, MSA, and PD, respectively, in each of whom the postmortem histopathological diagnosis differed from the final clinical diagnosis are described.
Neuroimaging Advances in Parkinson's Disease and Atypical Parkinsonian Syndromes
An updated presentation of well-established and emerging neuroimaging biomarkers are reviewed from the following modalities: structural magnetic resonance imaging (MRI), diffusion-weighted and diffusion tensor MRI, resting-state and task-based functional MRI, proton magnetic resonance spectroscopy, and single photon emission computed tomography.
Role of Neuroimaging on Differentiation of Parkinson's Disease and Its Related Diseases.
A diagnostic approach is provided for the differential diagnosis of PD and its related diseases in clinical practice using morphological imaging modalities (conventional MR imaging and neuromelanin MR imaging) and functional imagingmodalities that are clinically available in most hospitals.
Clinical and Imaging Markers of Prodromal Parkinson's Disease
The approach to prodromal PD is reviewed, with an emphasis on clinical and imaging markers and results from the neuroimaging study, a retrospective evaluation of a cohort of 39 participants who underwent DAT-SPECT scan as part of their follow up.
Emerging Treatment Approaches for Parkinson’s Disease
The promising regenerative cell-based and gene therapies, designed to treat the dopaminergic aspects of PD whilst limiting adverse effects, as well as novel approaches to reducing α-synuclein pathology are discussed.
Parkinson’s Disease: A Review from Pathophysiology to Treatment
Information is reviewed on the pathophysiology, symptomatology as well as the most current and relevant treatments of PD patients, which basically aims to control the symptoms, enabling better functional mobility and increasing life expectancy of the treated PD patients.
Epidemiology of Parkinson’s disease
A recent revision of the diagnostic criteria excludes postural instability as a fourth hallmark and defines supportive criteria, absolute exclusion criteria and red flags, and Revised diagnostic criteria are expected to improve the clinician´s accuracy in diagnosing PD.


Parkinson's disease and parkinsonism: neuropathology.
  • D. Dickson
  • Biology, Medicine
    Cold Spring Harbor perspectives in medicine
  • 2012
Given the population frequency of PD, α-synuclein pathology similar to that in PD, but not accompanied by neuronal loss, is relatively common (10% of people over 65 years of age) in neurologically normal individuals, leading to proposed staging schemes for PD progression.
The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.
  • W. Gibb, A. Lees
  • Medicine, Psychology
    Journal of neurology, neurosurgery, and psychiatry
  • 1988
Associated pathological findings suggest that cases of incidental Lewy body disease are presymptomatic cases of Parkinson's disease, and confirm the importance of age (time) in the evolution of the disease.
Identifying prodromal Parkinson's disease: Pre‐Motor disorders in Parkinson's disease
The evidence for the utility of olfaction, RBD, autonomic markers, visual changes, mood disorders, and cognitive loss as markers of prodromal PD and the potential sensitivity and specificity of these markers are summarized.
What genetics tells us about the causes and mechanisms of Parkinson's disease.
An impressive set of data in different model systems strongly suggest that mitochondrial dysfunction plays a central role in clinically similar, early-onset autosomal recessive PD forms caused by parkin and PINK1, and possibly DJ-1 gene mutations.
A tale on animal models of Parkinson's disease
During this journey of 25 years, both the significant contributions of the Parkinson's disease models and hurdles that remain to be overcome to one day cure this neurological disease are discussed.
The synaptic pathology of α-synuclein aggregation in dementia with Lewy bodies, Parkinson’s disease and Parkinson’s disease dementia
If presynaptic α-synuclein aggregation, not neuronal loss, is the key issue of the neurodegenerative process, then PD and DLB may eventually be treatable in the future and stem cell transplants are of limited use.
Disease duration and the integrity of the nigrostriatal system in Parkinson's disease.
The extent of nigrostriatal degeneration in patients with Parkinson's disease at different disease durations from time of diagnosis is investigated and loss of dopaminergic markers in the dorsal putamen occurs rapidly and is virtually complete by 4 years post-diagnosis.
The interplay of cholinergic function, attention, and falls in Parkinson's disease
It is feasible that cognition (namely, attention), visual hallucinations, falls, and gait are subserved by acetylcholine, and this is further explored in this clinically orientated review.
The progression of pathology in longitudinally followed patients with Parkinson’s disease
The pathological progression of longitudinally followed cases with levodopa-responsive Parkinson’s disease who came to autopsy during the Sydney Multicenter Study of Parkinson's disease is described, suggesting that widespread Lewy body pathology either occurs at the onset of clinical disease or rapidly infiltrates the brain.